Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
The PI3Kδ inhibitor zandelisib on intermittent dosing in ... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
0
Authors
Andrew Zelenetz
18 more
Andrew Zelenetz
•
Wojciech Jurczak
16 more
•
Pier Zinzani
Published
August 1, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Loading PDF viewer…
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
HemaSphere
Topics
Physics
Cancer Oncology
Medicine
Internal Medicine
Surgery
Show all topics
DOI
10.1002/hem3.138
License
CC-BY-NC-ND
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
HemaSphere
Topics
Physics
Cancer Oncology
Medicine
Internal Medicine
Surgery
Show all topics
DOI
10.1002/hem3.138
License
CC-BY-NC-ND
Other Formats
PDF
